Letrozole 2.5 - Adelphi Research

With the FDA’s 1997 approval, letrozole entered the medical field as an advanced option for postmenopausal breast cancer. Designed to block aromatase and thus lower estrogen, letrozole stands out for its effectiveness across small and large doses, even aiding estrogen-related issues from steroid use. However, users should be mindful of bone density and cholesterol changes. As the most potent inhibitor in its class, Femara’s influence remains prominent worldwide, and it often replaces older therapies for its strength and reliability​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Letrozole 2.5 by Adelphi Research, consult with your doctor or healthcare professional.